[
  {
    "ts": null,
    "headline": "Takeda says $4B TYK2 drug succeeds in large psoriasis studies",
    "summary": "The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.",
    "url": "https://finnhub.io/api/news?id=b1f53debd49fc12d52f89b4cd2a6e3db109d155e24a06628ff12bd5a7642bcc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766051100,
      "headline": "Takeda says $4B TYK2 drug succeeds in large psoriasis studies",
      "id": 137821754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.",
      "url": "https://finnhub.io/api/news?id=b1f53debd49fc12d52f89b4cd2a6e3db109d155e24a06628ff12bd5a7642bcc9"
    }
  }
]